Hyderabad Startup Launches RNA Foundry for Personalised mRNA Cancer Vaccines
Hyderabad-based biotech startup PopVax has launched an RNA Foundry to develop personalised mRNA cancer vaccines tailored to individual patients' tumour genetic mutations. Using AI and tumour sequencing, the facility designs and manufactures vaccines that train the immune system to target cancer cells, particularly for aggressive tumours resistant to conventional treatments. The process takes about 8-10 weeks and costs approximately Rs 2.84 crore. This initiative advances India's capabilities in RNA-based therapeutics and reflects growing global interest in personalised cancer immunotherapy.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 38/100.
Outlets measured: ndtv, firstpost. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (58–74/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
firstpost broke this story on 2 Nov, 07:13 am. Other outlets followed.